[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-kidney-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-kidney-injury":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,188,0,25,[9,45,77,100,126,151,179,203,223,255,279,300,322,352,375,399,422,449,475,505,528,550,580,609,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645232","analysis-of-continuous-kidney-replacement-therapy-ckrt-treatments-with-multiflux-hemofilters-using-regional-citrate-anticoagulation-rca-or-systemic-heparin-anticoagulation-100645232",false,"NCT07679568","Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation","Analysis of CKRT Treatments With multiFlux Hemofilters Using RCA or Systemic Heparin Anticoagulation","RCA-Flux","Inclusion Criteria:\n\nGeneral:\n\nPatients ≥ 18 years:\n\n* Informed consent signed and dated by the investigator; and\n\n  1. if patient is able to give consent: by the study patient\n  2. if patients unable to give consent: by the legal representative\u002Fspouse according to § 1358 BGB or\n  3. if an emergency situation is determined: by an independent consultant physician.\n\n     Pediatric Patients \\\u003C 18 years:\n* Informed consent signed and dated by legal representative and investigator\u002F authorized physician.\n* The minors have received the information referred to in Article 63(2) Medical Device Regulation (MDR) in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children. If able, the minors have to sign the informed consent, too.\n* The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator\n\nStudy specific:\n\n* Body weight ≥ 8kg\n* Acute Kidney Injury (AKI) with clinical indication for CKRT\n* Clinically estimated life expectancy greater than 3 days\n\nExclusion Criteria:\n\n* Any conditions which could interfere with the patient's ability to comply with the study\n* Patient or legal representative or authorized physician during emergency situation is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations\n* Participation in a different interventional clinical study during the preceding 30 days\n* Previous participation in the same study\n* Uncontrolled bleeding and coagulation disorders","ALL","1 Year",{"count":21,"type":22},62,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments. The multiFlux hemofilter is a single use device within the extracorporeal blood circuit during extracorporeal blood purification treatments for acute renal replacement therapies.",[26,27],"Acute Kidney Injury","Renal Failure",[29,30,31],"Continuous kidney replacement therapy","Regional citrate anticoagulation","Systemic heparin anticoagulation","NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":22},"2026-07",{"date":40,"type":22},"2027-12",{"name":42,"class":43},"Fresenius Medical Care Deutschland GmbH","INDUSTRY",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100644754","remimazolam-on-the-incidence-of-postoperative-acute-kidney-injury-100644754","NCT07674719","Remimazolam on the Incidence of Postoperative Acute Kidney Injury","The Effect of Intraoperative Remimazolam Administration on the Incidence of Postoperative Acute Kidney Injury After Hepatobiliary and Pancreatic Surgery : a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Ages 19 or older and under 85\n* Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical grade 1-3\n* Those who voluntarily consented to a written informed consent form prior to participation in the study\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)\n* Patients with hypersensitivity to propofol\n* Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma\n* Patients with severe or acute respiratory failure\n* Patients in shock or a coma\n* Patients taking TCA antidepressants\n* Patients with preoperative chronic kidney disease","19 Years","85 Years",{"count":55,"type":22},78,"INTERVENTIONAL",[58],"NA","We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.",[61,62,26,63,64,65,66],"Remimazolam","Propofol","Hemodynamic Stability","Hepatobiliary Surgery","Fluid Therapy","Fluid Therapy DURING SURGERY","2026-06-24",{"date":69,"type":36},"2026-06-29",{"date":71,"type":22},"2026-06-26",{"date":73,"type":22},"2028-06-26",{"name":75,"class":76},"Seoul National University Bundang Hospital","OTHER",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100644502","acute-kidney-injury-in-care-transitions-act-pragmatic-clinical-trial-100644502","NCT07670520","Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial","ACT","Inclusion Criteria:\n\n* Clinician subjects\n\n  * Hospital clinicians including physicians and advanced practice providers employed by Mayo Clinic and practicing at one of the four study sites\n  * Provide care for hospitalized patients with stage 2 or stage 3 acute kidney injury (AKI) who are expected to be discharged home and are not receiving dialysis\n* Patient subjects:\n\n  * Adults ≥18 years old\n  * Meet KDIGO consensus criteria for stage 2 (moderate) or 3 (severe) AKI\n  * Residence within the study catchment area (southern Minnesota, northern Iowa, or western Wisconsin)\n\nExclusion Criteria:\n\n* Clinician subjects: Physicians and advanced practice providers who:\n\n  * Care exclusively for pediatric patients (\\\u003C18 years)\n  * Care exclusively for patients on palliative care\n* Patient subjects\n\n  * Discharged to hospice care\n  * Require outpatient dialysis at discharge\n  * Are admitted from or expected to be discharged to a skilled nursing facility\n  * Dementia Diagnosis\n  * Have undergone solid organ transplant within the past 100 days\n  * Decline authorization for use of their medical records for research","18 Years",{"count":86,"type":22},2260,[58],"The purpose of this study is to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.",[26],"RECRUITING","2026-06-19",{"date":71,"type":36},{"date":94,"type":36},"2026-04-16",{"date":96,"type":22},"2030-12-31",{"name":98,"class":76},"Mayo Clinic",3,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":56,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100609524","phase-2-a-study-to-investigate-the-efficacy-safety-and-tolerability-of-azd4144in-participants-with-sepsis-associated-acute-kidney-injury-100609524","NCT07215702","A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.","A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)","SERENIA","Inclusion Criteria Age ≥ 18 to ≤ 80 years at the time of signing the informed consent. Participants who are admitted to an ICU or an equivalent critical-care unit.\n\nDiagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:\n\nA. Suspected or confirmed bacterial infection AND B. Acute increase of mSOFA score of 2 or more excluding renal component (change in score measured to account for participants that may meet mSOFA criteria from pre-existing organ dysfunction before the onset of infection).\n\nHaemodynamic therapy:\n\nA. 30 mL\u002Fkg or clinically appropriate volume resuscitation prior to randomisation.\n\nB. Vasopressor and\u002For inotrope therapy for sepsis-induced hypotension (eg, norepinephrine \\[noradrenaline\\], epinephrine \\[adrenaline\\], phenylephrine, dopamine, dobutamine) for ≥ 4 hours.\n\nDiagnosis of AKI, within 72 hours of sepsis diagnosis, with modified KDIGO Stage ≥ 1, defined as: Increase in SCr to ≥ 1.5 × baseline (outpatient \\[preferred\\] or admission pre-AKI reference). Timing of AKI diagnosis is defined as the time that the initial qualifying SCr was reported. AKI must persist after completion of initial volume resuscitation (30 mL\u002Fkg or as clinically indicated per investigator discretion).\n\nOutpatient pre-AKI reference eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2, if available within 2 weeks to 12 months prior to admission (preferred). If not available, admission pre-AKI reference eGFR ≥ 45 mL\u002Fmin\u002F1.73 m2 .\n\nBody weight ≥ 40 kg or ≤ 125 kg. Female or male, assigned at birth, inclusive of all gender identities. All FOCBP must have a negative pregnancy test at the Screening visit (Visit 1).\n\nContraception:\n\nA. Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods detailed in CSP from the time of first administration of study intervention administration until 100 days after the last dose of study intervention.\n\nB. FOCBP must not be lactating and must agree to use an approved method of highly effective contraception, as detailed in the CSP from the time of first administration of study intervention until 100 days after last dose of study intervention.\n\nCapable of giving signed informed consent (participant or LAR). Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research.\n\nExclusion Criteria Any clinical evidence which in the investigator's opinion makes it undesirable for the potential participant to enrol in the study.\n\nKnown history of Stage 4 or 5 CKD with documented sustained eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 prior to hospital admission.\n\nSepsis diagnosed \\> 7 days after hospital admission (to include from time of outside admission if patient transferred from another healthcare setting).\n\nAKI attributed to causes other than sepsis, including but not limited to compromised renal perfusion-related causes (surgical complication, acute abdominal aortic aneurysm, dissection, renal artery stenosis, etc), glomerular disease, acute interstitial nephritis, and medication toxicity.\n\nEvidence of recovery from AKI prior to randomisation defined as:\n\nA. A reduction of SCr to less than 1.5 times reference SCr in the last available local SoC laboratory result before randomisation or B. A \\> 25% reduction in SCr from peak SCr after volume resuscitation prior to randomisation.\n\nExpected survival from sepsis \\\u003C 24 hours. Expected survival \\\u003C 90 days due to chronic or pre-existing medical conditions other than SA-AKI Known history of renal transplant or bilateral nephrectomy. Permanent incapacitation. Incapacitation is defined as the inability to independently perform tasks essential to personal health and\u002For safety.\n\nActive cancer or cancer in remission for less than 2 years. Known history of immunodeficiency disease or currently receiving immunosuppressant therapy for non-sepsis related disease.\n\nSevere burns requiring ICU treatment. Sepsis attributed to confirmed or presumed fungal or viral infection at time of Screening.\n\nHas advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C).\n\nKnown history of cerebrovascular accident within the last 90 days. Known history of heart failure with reduced ejection fraction with documented ejection fraction ≤ 20% before sepsis diagnosis.\n\nKnown hypersensitivity to iohexol or known history of severe adverse reaction to iodinated contrast media.\n\nParticipants with known medical or psychological condition(s), or who, in the judgement of the investigator, should not participate in the study if they are unlikely to comply with study procedures, restrictions, and requirements.\n\nCurrent KRT (eg, continuous haemofiltration and haemodialysis\u002Fcontinuous kidney replacement therapy, intermittent haemodialysis, and peritoneal dialysis) or planned KRT (meaning KRT is scheduled, or the decision to initiate KRT has been made by the treating physician) at randomisation.\n\nCurrently receiving active treatment for malignancy.\n\nPotential participants will be excluded if they have received a certain class of medication during the weeks before enrollment or are anticipated to require a specific class of medication during the trial duration.\n\nParticipants with a known hypersensitivity to AZD4144 or any of the excipients of the product.\n\nReceipt of another IMP within 30 days, 5 half-lives, or the time frame of expected PD effect from most recent dose, whichever is longest.\n\nPrevious receipt of AZD4144. Active or planned treatment of sepsis with an extracorporeal haemoperfusion device.\n\nParticipation in any other concurrent ICU study which could impact participant clinical outcomes and confound results of this study to, including but not limited to volume resuscitation, vasopressor, or mechanical ventilation studies.\n\nPresence of anuria (≥ 12 hours) at randomisation. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead ECG, at Screening, as judged by the investigator.\n\nProlonged QTcF \\> 470 ms. Known history of QT prolongation associated with other medications that required discontinuation of that medication.\n\nCongenital long QT syndrome. Known history of ST-elevation myocardial infarction or non-ST-elevation myocardial infarction, with or without intervention by percutaneous coronary intervention or coronary artery bypass grafting within the last 90 days.\n\nVentricular arrhythmia requiring treatment. Known or presumed latent or active tuberculosis. Acute pancreatitis with no established source of infection. Undergoing extracorporeal membrane oxygenation (ECMO) at randomisation. Neutropenia: ANC \\\u003C 1.5 × 109\u002FL. Admitting diagnosis of rhabdomyolysis. Admitting diagnosis of trauma with CK \\> 15000 U\u002FL. Presumed nidus of infection in central nervous system. Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site).\n\nPrevious randomisation in the present study. For females only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.\n\nFirst infusion of IMP unable to be started within 36 hours of AKI diagnosis. Presence of a do-not-resuscitate order.","80 Years",{"count":110,"type":22},124,[112],"PHASE2","This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.",[115,26],"Sepsis",[115,26],{"date":118,"type":36},"2026-06-23",{"date":120,"type":36},"2026-02-10",{"date":122,"type":22},"2027-02-11",{"name":124,"class":43},"AstraZeneca",72,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":18,"minAge":84,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":56,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":4},"100524514","early-biomarker-kidney-injury-assessment-after-acumen-directed-fluid-management-in-cardiac-surgery-100524514","NCT06109714","Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery","BE-KIND","Inclusion Criteria:\n\n* Adult patients undergoing cardiopulmonary bypass\n* Procedure coronary artery bypass grafting, aortic valve replacement, or both\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old\n* Emergent surgery\n* Preoperative kidney disease (Cr \\> 2.0 or on renal replacement therapy)\n* Ejection fraction \\\u003C 40%\n* Incomplete data in medical record",true,"90 Years",{"count":136,"type":22},100,[58],"This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.",[140,26],"Renal Injury",[142,143,144],"Cardiac Surgery","Cardiac Surgery Induced Kidney Injury","Kidney Biomarkers",{"date":118,"type":36},{"date":147,"type":22},"2026-09-01",{"date":96,"type":22},{"name":150,"class":76},"University of Maryland, Baltimore",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":56,"phases":160,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":178},"100557271","phase-4-influence-of-human-albumin-supplementation-on-kidney-dysfunction-after-liver-transplantation-100557271","NCT06535945","Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation","HALT","Inclusion Criteria:\n\n* Male and female subjects equal or above 18 yrs old.\n* Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).\n* Capability of understanding the purpose and risks of the study.\n* Written informed consent\n\nExclusion Criteria:\n\n* Fulminant hepatitis\n* Kidney injury at baseline (Estimated Glomerular Filtration Rate \\\u003C 50 ml\u002Fmin in Modification of diet in renal disease-6) including hepatorenal syndrome\n* Use of an induction agent Basiliximab at liver transplantation\n* Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty",{"count":159,"type":22},400,[161],"PHASE4","To verify whether albumin administration to achieve serum concentration above 30g\u002FL (treated group) and its maintenance within plasmatic physiologic range (above 30 g\u002FL) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g\u002FL or below (control)).",[164,26],"Liver Transplantation",[166,167,168,26],"Liver","Transplantation","Albumin","2026-06-16",{"date":171,"type":36},"2026-06-17",{"date":173,"type":36},"2025-03-26",{"date":175,"type":22},"2028-04-26",{"name":177,"class":76},"Rennes University Hospital",8,{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":84,"enrollmentInfo":186,"targetDuration":4,"studyType":56,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100609285","phase-2-biomarker-and-renal-angina-validation-to-assess-heart-kidney-outcomes-after-amino-acid-therapy-100609285","NCT07212595","Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy","BRAVE-HEART","Inclusion Criteria:\n\n* Expected to be at high risk of developing acute kidney injury after cardiac surgery based on Age, The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) score, and anticipated cardiopulmonary bypass time\n* Age less than or equal to 18 years\n* Weight greater than or equal to 5 kilograms\n\nExclusion Criteria:\n\n* Preoperative extracorporeal organ support\n* History of chronic kidney disease\n* Known or suspected inborn errors of amino acid metabolism\n* Known hypersensitivity to amino acids\n* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \\> 3 times the upper limit of normal for age\u002Fgender\n* Preterm infants less than 6 months of age who were born at less than 36 weeks gestational age\n* Anuria at the time of randomization\n* Expected use of total parental nutrition (TPN) within the first 72 hours post-operatively",{"count":187,"type":22},30,[112],"The goal of the BRAVE-HEART study is to learn if an amino acid infusion can reduce the risk of developing acute kidney injury after cardiac surgery in children. The main questions it aims to answer are:\n\n1. Does an amino acid infusion decrease the number of participants with acute kidney injury?\n2. Does an amino acid infusion decrease the number of days that participants are on a ventilator after cardiac surgery?\n\nResearchers will compare amino acids to a placebo (a look-alike substance that contains no drug) to see if amino acids decrease the number of participants with acute kidney injury.\n\nParticipants will receive an amino acid or placebo infusion for up to 72 hours starting during cardiac surgery and only while in the operating room or the intensive care unit.",[26,191],"Mechanical Ventilation",[193,194,26,195],"Cardiac Bypass","Pediatric","Amino Acids","2026-06-15",{"date":171,"type":36},{"date":35,"type":22},{"date":200,"type":22},"2027-12-31",{"name":202,"class":76},"Dana Fuhrman",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":44},"100327767","does-urinary-timp2-and-igfbp7-can-identify-high-risk-patients-of-progression-from-mild-and-moderate-to-severe-acute-kidney-injury-during-septic-shock-100327767","NCT03547414","Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock?","Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock? HEMOCHECK","HEMOCHECK","Inclusion Criteria:\n\n* Age 18 or over\n* Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines\n* AKI, characterized by a KDIGO score ≥ 1\n* Social security coverage\n\nExclusion Criteria:\n\n* AKI requiring emergency RRT (in the critical care physician's opinion).\n* Anuria\n* Stage 4-5 chronic kidney failure with a GFR below 30 ml\u002Fmin.\n* Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)\n* Obstructive AKI\n* Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis)\n* Pregnancy or breastfeeding\n* Legal guardianship or lack of social security coverage.\n* Cardiocirculatory arrest\n* Life expectancy \\\u003C48 hours.\n* Child C cirrhosis\n* Prior occurrence of AKI during the current hospital stay\n* Transplantation\n* Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion",{"count":212,"type":22},110,"Septic shock is one of the leading causes of death in patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in almost 50% of septic patients and is associated with significant mortality. Progression to the last stage (KDIGO stage 3) of AKI is an important step in the disease, as it usually requires initiation of RRT. Renal biomarkers are unable to accurately identify those patients who will progress to severe AKI (KDIGO 3). However, identification of patients at risk of progression to severe AKI could help the clinician to initiate optimal therapy including RRT. A new urine test, the Nephrocheck™ corresponding to the product of the urinary concentrations of 2 markers of renal tubule injury (TIMP2 and IGFBP7) has been validated. The Investigator have already performed two previous studies including septic shock patients (AKICHECK and BIOOCHECK). those previous datas will be reanalysed to examine whether the new urinary biomarkers TIMP2 and IGFBP7 can predict progression within 24 hours and 72 hours from mild and moderate (KDIGO 1 or 2) to severe AKI (KDIGO 3) in patients with septic shock.\n\n-All the datas required will be collected from two previous studies (AKICHECK and BIOCHECK) performed in 3 centers: Amiens medical ICU, Melun medico surgical ICU and Montpellier Medical ICU.",[26,215],"Septic Shock",{"date":169,"type":36},{"date":218,"type":36},"2018-05-16",{"date":220,"type":22},"2026-06",{"name":222,"class":76},"Centre Hospitalier Universitaire, Amiens",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":232,"conditions":233,"keywords":238,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100642154","volume-removal-intolerance-during-net-ultrafiltration-in-acute-kidney-injury-patients-100642154","NCT07643597","Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients","VINKO","Inclusion Criteria:\n\n* Age ≥18 years\n* Admission to an Intensive Care Unit\n* Acute kidney injury according to KDIGO criteria\n* Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration\n* Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team\n\nExclusion Criteria:\n\n* Chronic kidney replacement therapy prior to ICU admission\n* Pregnancy\n* Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period\n* Inability to perform hemodynamic or perfusion assessment\n* Extracorporeal membrane oxygenation (ECMO)\n* Refusal to participate in the study",{"count":231,"type":22},128,"Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process.\n\nThe purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance.\n\nThe investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.",[26,234,235,236,237],"Fluid Overload","Fluid Overload in Dialysis Patients","Critical Illness","Renal Replacement Therapy for Acute Kidney Injury in ICU",[239,240,241,242,243,234,244,245],"Net Ultrafiltration","Continuous Renal Replacement Therapy","Fluid Removal","Ultrafiltration Intolerance","Tissue Hypoperfusion","VExUS","Point-of-Care Ultrasound","2026-06-13",{"date":169,"type":36},{"date":249,"type":22},"2026-07-06",{"date":251,"type":22},"2027-12-01",{"name":253,"class":76},"Hospital Las Higueras",10,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":56,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":44},"100641871","the-effect-of-standard-vs-shorter-filter-lifespan-during-continuous-renal-replacement-therapy-100641871","NCT07630220","The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy","The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury - a Feasibility Randomized Controlled Trial","SPECIAL","Inclusion Criteria:\n\n1. Adult ≥ 18 years\n2. Critically ill patients with severe AKI consistent with KDIGO stage 3 and an absolute indication for CRRT\n3. Written consent form from the patient or legal representative or authorized representative or emergency inclusion\n\nExclusion Criteria:\n\n1. End-stage kidney disease or chronic dialysis dependence\n2. Chronic kidney disease with eGFR\\\u003C20ml\u002Fmin\u002F1.73 m²\n3. Prior kidney transplant\n4. Prior renal replacement therapy during the index admission before randomization\n5. Glomerulonephritis, interstitial nephritis, vasculitis\n6. Patients on immunosuppression (above the cushing threshold)\n7. Patients with chronic inflammatory diseases (e.g. arthritis, HIV with a CD4 count of \\\u003C 0.05 x 10E\u002Fl)\n8. Do-not resuscitate order\n9. Persons with any kind of dependency on the investigator or employed by the sponsor\n10. Patients participating in an interventional study involving measures to influence the immune system",{"count":136,"type":22},[58],"This study aims to investigate shorter vs. standard filter lifespans in critically ill patients receiving continuous renal replacement therapy (CRRT) for acute kidney injury (AKI). The aim of this trial is to reliably implement,scheduled filter changes and to investigate whether shorter filter lifetime is associated with a lower incidence in rate of new infections.",[26],[268,269,270,271],"Continuous Renal Replacement Therapy (CRRT)","Infection","filter change","critical illness","2026-06-10",{"date":196,"type":36},{"date":220,"type":22},{"date":276,"type":22},"2028-06",{"name":278,"class":76},"Universität Münster",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":56,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100506826","phase-2-lsalt-peptide-for-prevention-or-attenuation-of-acute-kidney-injury-aki-in-patients-undergoing-on-pump-cardiac-surgery-100506826","NCT05879432","LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery","Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery","Inclusion Criteria:\n\n1. Male and female ≥ 18 years of age.\n2. Scheduled for a non-emergent coronary and\u002For valve surgery procedure requiring on-pump cardiopulmonary bypass including but not limited to:\n\n   * Coronary artery bypass graft (CABG) alone\n   * CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair\n   * Aortic valve replacement or repair alone, with or without aortic root repair\n   * Mitral, tricuspid, or pulmonic valve replacement or repair alone\n   * Simultaneous replacement of several cardiac valves.\n3. Have the following AKI risk factors:\n\n   * CKD Stage 3 (CKD-EPI eGFR ≥ 30 and \\\u003C 60 mL\u002Fmin\u002F1.73 m2) and ONE or more of the following additional risk factors OR\n   * CKD Stage 2 (CKD-EPI eGFR ≥ 60 and \\\u003C 90 mL\u002Fmin\u002F1.73 m2) and ONE or more of the following additional risk factors:\n\n     * Age ≥ 75 years;\n     * Combined valve \\& coronary artery surgery;\n     * Left ventricular ejection fraction (LVEF) ≤ 35% by invasive or noninvasive techniques;\n     * Urinary (TIMP-2 x IGFBP7) \\> 0.3\n     * Diabetes mellitus\n     * Hypertension\n     * Hyperlipidemia\n4. Sexually active women of child-bearing potential (WCBP) must be using a medically acceptable method of birth control throughout the study and for at least 1 day following the end of study and have a negative urine pregnancy test at the Screening visit. A WCBP is defined as a female who is biologically capable of becoming pregnant. A medically acceptable method of birth control includes intrauterine devices in place for at least 3 months, surgical sterilization, or the implant. In patients who are not sexually active, abstinence is an acceptable form of birth control and urine will be tested per protocol. Women who are of nonchild-bearing potential, i.e., post-menopause, must have this condition captured in their medical history. Pregnant women and nursing mothers are excluded from this study.\n5. Patient or Legally Authorized Representative (LAR) is available and willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures.\n\nExclusion Criteria:\n\n1. The presence of AKI (KDIGO criteria) at the time of randomization\n2. Off-pump cardiac surgery\n3. Surgery to be performed under conditions of circulatory arrest or hypothermia with rectal temperature \\\u003C 28°C (82.4° F)\n4. Severe chronic kidney disease: CKD-eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2) OR requiring dialysis\n5. Imminent or recent surgery for aortic dissection\n6. Surgery to correct a major congenital heart defect (e.g., Tetralogy of Fallot, transposition of the great vessels, single ventricle, or Ebstein's anomaly. Bicuspid aortic valve is not considered a congenital heart defect)\n7. Known history of active cancer which may interfere with interpretation of the results of this study\n8. Known or suspected sepsis at time of screening\n9. Pregnancy or lactation\n10. Known hypersensitivity to the study drug or any of its excipients\n11. Treatment with an investigational drug or participation in an interventional trial within 30 days prior to the first dose of study drug and throughout the study\n12. Any disease processes or confounding variables that would inappropriately alter the outcome of the study in the opinion of the investigator\n13. Inability to comply with the requirements of the study protocol.",{"count":287,"type":22},240,[112],"To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria:\n\n1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol\u002FL (≥0.3 mg\u002FdL) within 7 days; OR\n2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR\n3. Urine output \\\u003C 0.5 mL\u002Fkg\u002Fh for \\>6 hours.",[26,142],{"date":292,"type":36},"2026-06-12",{"date":294,"type":36},"2024-03-08",{"date":296,"type":22},"2027-08",{"name":298,"class":43},"Arch Biopartners Inc.",9,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":56,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":321},"100501237","uptake-using-personalized-risk-and-digital-tools-to-guide-transitions-following-acute-kidney-events-100501237","NCT05806645","UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events","UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events- A Pragmatic Randomized Controlled Trial in Connect Care","UPTAKE-1","Inclusion Criteria:\n\n(all of)\n\n* Age ≥ 18 years old\n* Hospitalized at site using AHS EHR\n* Acute Kidney Injury (Stage 1-3) identified in hospital per KDIGO guideline criteria\n\nExclusion Criteria:\n\n(any of)\n\n* Pre-hospitalization advanced CKD: eGFR\\\u003C30 mL\u002Fmin\u002F1.73m2\n* Pre-hospitalization dialysis\n* Very low risk (\\\u003C1% risk) of advanced CKD\n* Non-Alberta resident\n* Palliative goals of care\n* Enrolled in the UPTAKE VC Trial\n* Admitted under a nephrologist at time of discharge\n* Dialysis on at least 2 days in the last week prior to discharge\n* Receiving apheresis\n* Kidney transplant recipient\n* Kidney transplant donor\n* Diagnosis of Glomerulonephritis\n* Cirrhosis AND complication of cirrhosis in medical history or active problem list (ascites, varices, hepatic encephalopathy, hepatorenal syndrome)",{"count":309,"type":22},6046,[58],"Nearly one in ten people who are hospitalized in Canada develop a complication with sudden loss of kidney function, called acute kidney injury (AKI). AKI may lead to other severe health problems after discharge home, such as kidney failure requiring dialysis treatment, heart failure, heart attacks, stroke, and even premature death. Discharge from hospital to home can be a difficult transition where there are often gaps in identification, communication, care coordination, education, and planning of care for AKI. The study team will co-design and evaluate a tailored post-discharge care plan that is based on the risk of later kidney problems and uses currently available, yet untapped digital innovation to improve the health and experience of people with AKI.\n\nThis study will be built into Alberta's new Epic Systems based provincial electronic health record (EHR). The plan is to use digital tools in the EHR to identify all people in Alberta hospitals that have had an AKI event and are at increased risk of long-term complications. Half will randomly be assigned to receive a tailored care plan based on their risk at hospital discharge while the other half will receive care as it is currently provided by their healthcare team. The electronic health system will automatically calculate a patient's risk and report this risk in their chart along with recommendations for care. The study team includes patients, healthcare providers, and health system decision makers needed to co-develop the proposed strategy and introduce the changes needed to deliver this intervention. The investigators will study whether this strategy can reduce health problems that may happen after AKI including death, chronic kidney disease (CKD), kidney failure, heart attacks, and stroke. The investigators will also determine if the approach improves patient experience during the transition from hospital to home. This study has the potential to revolutionize how we care for people that leave hospital after having AKI.",[26],"2026-06-08",{"date":272,"type":36},{"date":316,"type":36},"2025-02-12",{"date":318,"type":22},"2029-09",{"name":320,"class":76},"University of Alberta",2,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":44},"100643768","acute-kidney-injury-in-upper-gi-bleeding-patients-100643768","NCT07636083","Acute Kidney Injury in Upper GI Bleeding Patients","Acute Kidney Injury Following Upper Gastrointestinal Bleeding: Incidence and Predictors","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients presenting with clinical features suggestive of acute upper gastrointestinal bleeding (UGIB), including hematemesis, coffee-ground vomiting, or melena\n* Diagnosis of UGIB confirmed by upper gastrointestinal endoscopy or strong clinical evidence when endoscopy is not immediately available\n* Patients admitted to Sohag University Hospitals (medical wards or intensive care unit)\n* Availability of renal function data, including at least one serum creatinine measurement at admission and serial measurements during hospitalization\n* Availability of baseline renal function (previous serum creatinine within 3-12 months) or estimable baseline during hospitalization\n\nExclusion Criteria:\n\n* Patients with end-stage renal disease (ESRD) on chronic dialysis\n* Patients with a history of renal transplantation\n* Patients with advanced chronic kidney disease stage 5 (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²) not on dialysis\n* Patients with lower gastrointestinal bleeding\n* Patients with incomplete or missing essential renal function data\n* Patients discharged or deceased within 24 hours of hospital admission\n* Pregnant patients\n* Patients with acute kidney injury at presentation due to causes other than UGIB",{"count":330,"type":22},200,"This study aims to evaluate the incidence of acute kidney injury (AKI) among patients presenting with acute upper gastrointestinal bleeding (UGIB) at Sohag University Hospitals, and to identify predictors associated with renal impairment in these patients.",[333,26],"Upper Gastrointestinal Bleeding",[335,336,337,338,339,340,341,342],"UGIB","AKI","Renal Impairment","Gastrointestinal Hemorrhage","Serum Creatinine","Kidney Function","Variceal Bleeding","Non-variceal Bleeding","2026-06-04",{"date":345,"type":36},"2026-06-09",{"date":347,"type":22},"2026-05-15",{"date":349,"type":22},"2027-05-15",{"name":351,"class":76},"Sohag University",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":56,"phases":362,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":373,"locationsCount":321},"100611121","phase-1-labile-iron-removal-by-adding-the-iron-chelator-mex-cd1-to-dialysate-in-sepsis-associated-acute-kidney-injury-100611121","NCT07236463","Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury","Performance and Safety of Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate During Continuous Veno-venous Hemodialysis for Sepsis-associated AKI: Protocol for a Phase I-II Randomized Crossover Pilot Study.","IRON-IC","Inclusion Criteria:\n\n* Adult patients (≥18 years) admitted to ICU with sepsis-associated AKI requiring CRRT\n* Sepsis defined according to SEPSIS-3 criteria (suspected\u002Fdocumented infection with organ dysfunction indicated by ≥2-point increase in SOFA \\[Sequential Organ Failure Assessment\\] score)\n* AKI Stage 3 per KDIGO (Kidney Disease: Improving Global Outcomes) criteria: acute rise in serum creatinine ≥3 times baseline or serum creatinine ≥4 mg\u002FdL or urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours or anuria (urine output \\\u003C100ml) for ≥12 hours\n* Indications for CRRT: refractory hyperkalemia (\\>6 mmol\u002FL) or refractory metabolic acidosis (pH \\\u003C 7.20) or acute pulmonary edema unresponsive to medical management or urine output \\\u003C0.3 ml\u002Fkg\u002Fhour or anuria (urine output \\\u003C100ml) persistent for 48 hours and refractory to medical treatment\n* Informed consent obtained from patient or legal representative\n* Affiliated with or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* Known shellfish allergy\n* Moribund status with life expectancy too low to benefit\n* Concurrent participation in another interventional study\n* Exclusion period defined by another study\n* Under legal protection (guardianship or curatorship)\n* Inability to obtain informed consent from patient or representative\n* Pregnant, parturient, or breastfeeding women",{"count":361,"type":22},14,[363,112],"PHASE1","The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the intensive care unit (ICU). The main questions it aims to answer are:\n\nDoes adding MEX-CD1 to the dialysis fluid increase the amount of iron removed during dialysis? Is using MEX-CD1 in dialysis fluid safe for patients?\n\nParticipants will:\n\nBe adults in the ICU with sepsis-associated AKI who need continuous dialysis (renal replacement therapy) Receive two 24-hour dialysis sessions: one with standard dialysis fluid and one with dialysis fluid containing MEX-CD1 Serve as their own control, meaning they will receive both treatments\n\nResearchers will measure:\n\nThe amount of iron removed in the dialysis waste fluid (primary outcome) Blood levels of iron Changes in other trace elements Markers of inflammation and oxidative stress Safety outcomes up to 28 days after treatment This is a pilot study being done at a single hospital in France.",[26,115],[26,115,240,367,368],"Iron Chelating Agents","Intensive Care Unit",{"date":370,"type":36},"2026-06-05",{"date":343,"type":36},{"date":276,"type":22},{"name":374,"class":76},"Centre Hospitalier Universitaire de Nīmes",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":108,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":44},"100643494","assessment-of-renal-perfusion-using-ultrasound-and-near-infrared-spectroscopy-in-patients-undergoing-minimally-invasive-abdominal-surgery-100643494","NCT07635160","Assessment of Renal Perfusion Using Ultrasound and Near-Infrared Spectroscopy in Patients Undergoing Minimally Invasive Abdominal Surgery","Prospective Observational Evaluation of Renal Perfusion Using Doppler Ultrasonography and Near-Infrared Spectroscopy in Patients Undergoing Elective Minimally Invasive Abdominal Surgery","RRI-NIRS","Inclusion Criteria:\n\n* Patients aged 18 to 80 years\n* Patients with ASA physical status I, II, or III\n* Patients undergoing elective minimally invasive abdominal surgery for any reason\n* Patients whose expected surgical duration is longer than 1 hour\n\nExclusion Criteria:\n\n* Body mass index greater than 35 kg\u002Fm²\n* Severe respiratory system disease\n* Severe heart failure, NYHA class III-IV\n* Presence of a cardiac pacemaker or cardiac defibrillator implant\n* Progressive neuromuscular disease\n* High intra-abdominal pressure\n* Sudden deterioration of general condition\n* Incomplete clinical or laboratory data\n* Refusal to participate in the study\n* Conversion to open surgery",{"count":384,"type":22},51,"This prospective observational study aims to evaluate renal perfusion in adult patients undergoing elective minimally invasive abdominal surgery. Renal perfusion will be assessed using two non-invasive monitoring techniques: Doppler ultrasonography-derived Renal Resistive Index (RRI) and Near-Infrared Spectroscopy (NIRS)-derived renal regional oxygen saturation (rSO₂).\n\nMeasurements will be obtained at predefined perioperative time points, including after induction of anesthesia, during pneumoperitoneum, before extubation, and during the early postoperative period. Perioperative changes in renal perfusion parameters will be analyzed and correlated with clinical variables such as intra-abdominal pressure, pneumoperitoneum duration, hemodynamic parameters, fluid administration, urine output, and postoperative renal function.\n\nThe study also aims to investigate the relationship between intraoperative renal perfusion changes and the development of postoperative acute kidney injury. The findings may contribute to improved perioperative monitoring and optimization of renal perfusion during minimally invasive abdominal surgery.",[387,388,26],"Renal Perfusion","Minimally Invasive Surgical Procedures",[390],"Kidney Perfusion,Renal Resistive Index,Near-Infrared Spectroscopy,Acute Kidney Injury,Laparoscopic Surgery","2026-06-03",{"date":345,"type":36},{"date":394,"type":36},"2026-01-07",{"date":396,"type":22},"2027-01-07",{"name":398,"class":76},"Istanbul University - Cerrahpasa",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":134,"enrollmentInfo":406,"targetDuration":4,"studyType":56,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100632793","phase-4-nafamostat-mesylate-versus-regional-citrate-anticoagulation-for-continuous-renal-replacement-therapy-in-sepsis-associated-acute-kidney-injury-100632793","NCT07518303","Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury","NICE-AKI","Inclusion Criteria:\n\n* Age 18 to 90 years, inclusive, regardless of sex.\n* Meets Sepsis 3.0 diagnostic criteria and develops acute kidney injury within 7 days after the diagnosis of sepsis.\n* After adequate resuscitation, meets KDIGO 2012 stage 2 or stage 3 acute kidney injury criteria, including any of the following:\n\nSerum creatinine increased to more than 3 times baseline; or Serum creatinine ≥4.0 mg\u002FdL \\[353.6 μmol\u002FL\\]; or Urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours; or Anuria, defined as extremely low or absent urine output, lasting ≥12 hours.\n\nOr has an indication for CRRT, including any of the following:\n\nBlood urea nitrogen \\>150 mg\u002FdL; or Serum potassium \\>6 mmol\u002FL; or pH \\\u003C7.15; or Organ edema and\u002For fluid overload in the setting of AKI that is refractory to diuretic therapy.\n\n* Expected duration of CRRT treatment \\>48 hours.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Requirement for therapeutic anticoagulation, such as pulmonary embolism or deep vein thrombosis.\n* Contraindication to systemic anticoagulation.\n* Hemolytic uremic syndrome or thrombotic thrombocytopenic purpura.\n* Acute liver failure and\u002For shock with persistent severe lactic acidosis, defined as two consecutive measurements of pH \\\u003C7.2 lasting for more than 2 hours, with lactate \\>72.1 mg\u002FdL \\[8 mmol\u002FL\\].\n* Chronic kidney disease requiring long-term regular dialysis.\n* Acute kidney injury caused by permanent bilateral renal artery occlusion or surgical injury.\n* Acute kidney injury caused by glomerulonephritis, interstitial nephritis, or vasculitis.\n* Known allergy to study drugs, including nafamostat mesylate, sodium citrate, or their excipients.\n* Kidney transplantation within 1 year.\n* Planning pregnancy in the near term, pregnancy, or lactation.\n* HIV infection.\n* Only adsorptive filters such as oXiris are available at study enrollment.\n* Participation in another clinical trial within the previous 3 months.\n* Judged by the investigator to be in a moribund state or unlikely to complete the study intervention and primary outcome assessment, including but not limited to expected death within 24 hours after enrollment, decision for do-not-resuscitate order or limitation\u002Fwithdrawal of life-sustaining treatment, or planned abandonment of active treatment and self-discharge within 24 hours due to terminal disease or patient\u002Ffamily preference.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for enrollment.",{"count":407,"type":22},1162,[161],"This multicenter, randomized, open-label, active-controlled, parallel-group trial will evaluate the efficacy and safety of nafamostat mesylate anticoagulation compared with regional citrate anticoagulation in adult patients with sepsis-associated acute kidney injury requiring continuous renal replacement therapy. Eligible participants will be randomized in a 1:1 ratio to receive either nafamostat mesylate or regional citrate anticoagulation during CRRT. The primary outcome is MAKE30, a composite of all-cause mortality, new or ongoing renal replacement therapy, or persistent renal dysfunction within 30 days after randomization. Secondary outcomes include filter lifespan, CRRT-free days, 30-day all-cause mortality, renal replacement therapy status, persistent renal dysfunction, ICU and hospital mortality, length of stay, CRRT duration, major bleeding, new bloodstream infection during ICU stay, SOFA score, number of filters used, and protocol-defined safety outcomes.",[115,26,268],[412,268,115,413,414],"Nafamostat Mesylate","Acute Kidney Injury (AKI)","Randomized Clinical Trial (RCT)","2026-06-01",{"date":391,"type":36},{"date":272,"type":22},{"date":419,"type":22},"2028-12-10",{"name":421,"class":76},"Jianfeng Xie",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":56,"phases":431,"briefSummary":432,"conditions":433,"keywords":437,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":99},"100640169","initial-drainage-method-and-flexible-ureteroscopy-outcomes-in-calculous-anuria-100640169","NCT07627880","Initial Drainage Method and Flexible Ureteroscopy Outcomes in Calculous Anuria","Impact of Initial Drainage Method on Flexible Ureteroscopy Outcomes in Patients Presenting With Calculous Anuria: A Multicenter Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Calculous anuria secondary to a single upper ureteral stone.\n* Solitary functioning kidney, whether anatomical or functional.\n* Single upper ureteral stone confirmed by non-contrast computed tomography.\n* Stone size from 6 mm to 20 mm in maximum diameter.\n* Patient considered suitable for either initial JJ ureteral stent drainage or percutaneous nephrostomy drainage.\n* Candidate for definitive treatment by flexible ureteroscopy\u002Fretrograde intrarenal surgery.\n* Documented renal functional improvement and clinical stabilization before definitive RIRS.\n* Negative or appropriately treated urine culture before definitive RIRS.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Multiple stones or bilateral stones not fitting the solitary-kidney study design.\n* Renal pelvic, distal ureteral, or multiple ipsilateral stones.\n* Stone burden greater than 20 mm.\n* Septic shock, hemodynamic instability, or need for emergency dialysis at presentation.\n* Pyonephrosis requiring a non-randomized drainage decision.\n* Anatomical abnormalities affecting endoscopic access, such as horseshoe kidney, pelvic kidney, ureterocele, or ureteral stricture.\n* Previous ipsilateral ureteral reconstructive surgery.\n* Uncorrected coagulopathy.\n* Pregnancy.\n* Genitourinary malignancy.\n* Inability to complete follow-up.",{"count":430,"type":22},90,[58],"Calculous anuria caused by obstructing upper ureteral stones in a solitary functioning kidney is a urological emergency requiring urgent decompression. Both retrograde JJ ureteral stenting and percutaneous nephrostomy are commonly used emergency drainage methods. However, limited evidence is available regarding whether the initial drainage method affects subsequent definitive flexible ureteroscopy\u002Fretrograde intrarenal surgery outcomes.\n\nThis multicenter prospective randomized controlled trial will compare emergency JJ ureteral stent drainage versus percutaneous nephrostomy drainage in adult patients presenting with calculous anuria due to a single upper ureteral stone in a solitary functioning kidney. After renal functional improvement, clinical stabilization, and appropriate urine culture management, all participants will undergo standardized definitive flexible ureteroscopy\u002Fretrograde intrarenal surgery. The study will assess renal functional recovery, first-session surgical success, stone-free rate, operative parameters, complications, and microbiological outcomes.",[434,435,436,26],"Calculous Anuria","Upper Ureteral Stone","Obstructive Uropathy",[438,439,440],"Percutaneous nephrostomy","Double-J ureteral stent","Retrograde intrarenal surgery","2026-05-30",{"date":343,"type":36},{"date":444,"type":36},"2026-05-06",{"date":446,"type":22},"2027-04",{"name":448,"class":76},"Beni-Suef University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":56,"phases":457,"briefSummary":458,"conditions":459,"keywords":462,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":474,"locationsCount":44},"100639013","phase-2-intravesical-aminophylline-for-urgent-ureteral-stenting-in-acute-calculous-anuria-100639013","NCT07617948","Intravesical Aminophylline for Urgent Ureteral Stenting in Acute Calculous Anuria","Intravesical Aminophylline-Assisted Urgent Retrograde Ureteral Stenting for Acute Calculous Anuria: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute calculous anuria due to ureteral stone obstruction in a solitary functioning kidney.\n3. Obstruction confirmed by pelvi-abdominal ultrasound and computed tomography of the urinary tract.\n4. Clinical and laboratory evidence of acute renal impairment, including oliguria or anuria and serum creatinine \\>2 mg\u002FdL.\n5. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to aminophylline, theophylline, or other methylxanthines.\n2. Evidence of active urinary tract infection or urosepsis.\n3. Previous history of ureteral stricture or major urinary tract reconstructive surgery.\n4. Hemodynamic instability requiring immediate life-saving measures before urological intervention.\n5. Pregnancy.",{"count":125,"type":22},[112],"Acute calculous anuria is a urological emergency caused by ureteral stone obstruction in a solitary functioning kidney or bilateral ureteral obstruction. Urgent decompression of the upper urinary tract is required to restore urine drainage and prevent further renal impairment.\n\nThis prospective randomized double-blind controlled trial will evaluate whether intravesical aminophylline can facilitate urgent retrograde ureteral stenting in adult patients with acute calculous anuria due to ureteral stones. Eligible patients will be randomly assigned to receive either intravesical aminophylline diluted in normal saline or placebo saline before attempted retrograde Double-J ureteral stent placement.\n\nThe primary outcome is technical success, defined as successful placement of a Double-J ureteral stent across the obstructing stone without the need for percutaneous nephrostomy. Secondary outcomes include stenting time, intraoperative complications, renal function recovery, postoperative pain, analgesic requirement, and the need for alternative drainage.",[460,461,436,26],"Acute Calculous Anuria","Ureteral Calculi",[463,464,465,466,467],"Intravesical aminophylline","Retrograde ureteral stenting","Acute calculous anuria","Emergency urinary drainage","Double-J stent","2026-05-29",{"date":470,"type":36},"2026-06-02",{"date":472,"type":36},"2026-04-08",{"date":446,"type":22},{"name":448,"class":76},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":56,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":501,"leadSponsor":503,"locationsCount":4},"100639725","coordinated-communication-education-and-care-transitions-after-acute-kidney-injury-connect-aki--a-pilot-randomized-controlled-trial-100639725","NCT07626268","COordiNated CommuNication, Education, and Care Transitions After Acute Kidney Injury (CONNECT-AKI)- A Pilot Randomized Controlled Trial","CONNECT-AKI: COordiNated CommuNication, Education, and Care Transitions After Acute Kidney Injury - A Pilot Randomized Controlled Trial","CONNECT-AKI","Inclusion Criteria:\n\n* Age 18 years or older\n* Hospitalized with Stage 2 or Stage 3 acute kidney injury\n* Kidney function has not returned to baseline at the time of hospital discharge\n* Able to communicate in English\n* Able to provide informed consent\n* Willing and able to participate in study procedures independently or with assistance from a patient-designated care partner\n\nExclusion Criteria:\n\n* Acute kidney injury requiring ongoing dialysis at the time of hospital discharge\n* End-stage kidney disease\n* Kidney transplant recipient\n* Currently pregnant\n* Documented cognitive impairment that precludes informed consent\n* Receiving hospice or comfort-focused end-of-life care",{"count":484,"type":22},160,[58],"The goal of this clinical trial is to learn whether different ways of providing information and follow-up support after acute kidney injury, also called AKI, can improve care transitions for adults being discharged from the hospital. AKI is a sudden decrease in kidney function that can occur during a hospital stay.\n\nThe main questions this study aims to answer are:\n\n* Does an AKI discharge summary template improve communication about AKI after hospital discharge?\n* Does a chat-based educational messaging program improve patient understanding of AKI and support follow-up care after hospital discharge?\n* Researchers will compare usual care, an AKI discharge summary template, a chat-based educational messaging program, and the combination of the discharge summary template plus chat-based messaging.\n\nResearchers will compare four groups:\n\n* Usual care\n* An AKI discharge summary template\n* A chat-based educational messaging program\n* Both the AKI discharge summary template and the chat-based educational messaging program\n\nParticipants will complete questionnaires at the start of the study and about 4 weeks after hospital discharge. Participants will also receive a brief phone call about 3 months after discharge, and the research team will review their medical record for information about follow-up care, lab testing, emergency department visits, and hospital readmissions.",[26,413],[489,336,490,491,492,493,494,495,496,497,498],"Acute kidney injury","Hospital discharge","Care transitions","Post-discharge care","Patient education","Discharge communication","Discharge summary","Hospital readmission","Chat-based education","Digital health",{"date":343,"type":36},{"date":415,"type":22},{"date":502,"type":22},"2027-10-30",{"name":504,"class":76},"Northwell Health",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":56,"phases":515,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":44},"100639172","phase-2-study-of-the-relaxin-agonist-r2r01-in-patients-at-high-risk-for-cardiac-surgery-associated--acute-kidney-injury-100639172","NCT07625553","Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury","A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury","CSA-AKI","Inclusion Criteria:\n\n* Patient is able to communicate well with the Investigator, understands and is willing to comply with all requirements of the study, and understands and signs the written informed consent form (ICF).\n* At least 18 years of age.\n* Subject is scheduled for non-emergent CABG (single or multiple vessels), valve surgery (single or multiple valves), surgery of the ascending part of the aorta, or a combination of the above, involving cardiopulmonary bypass (CPB), AND risk factors for acute kidney injury (AKI) are present (at screening) as specified below:\n\n  1. If only one type of surgery is scheduled at least two AKI risk factors should be present\n  2. If any combined surgery is scheduled at least one AKI risk factor should be present\n* Have stable renal function per Investigator assessment.\n* Subject agrees not to participate in another interventional study after signing the ICF and until the end of study (EoS) visit has been completed.\n* Both female patients, as well as female partners of male patients who are of childbearing potential must be willing to not become pregnant for the complete duration of the study until 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Patient currently enrolled into another interventional clinical trial.\n* Subject is scheduled for emergent surgery.\n* Cardiac surgery planned to be performed \"off-pump\" without CPB.\n* Expected CPB duration \\\u003C60 minutes.\n* Body weight \\\u003C50 kg; \\>120 kg.\n* Presence of AKI (KDIGO criteria) at the time of randomization.\n* Current, prior, or scheduled renal replacement therapy.\n* Patients who are post-nephrectomy.\n* Patients with CKD of equal or more than stage IV (GFR≤30 ml\u002Fmin\u002F1.73 m2).\n* Patient with a kidney transplant.\n* Subject has a known or suspected glomerulonephritis at the time of randomization.\n* Cardiogenic shock, hemodynamic instability, mechanical ventilation, intra-aortic balloon pump (IABP), left ventricular assist device (LVAD) or other forms of mechanical circulatory support (MCS), within 7 days prior to surgery.\n* Patient received inotropes or vasopressors within 48 hours prior to the day of surgery.\n* Known or suspected sepsis.\n* Confirmed or suspected endocarditis\n* Other current active infection requiring antibiotic treatment.\n* Patient has severe liver disease (Child-Pugh score \\>7 points).\n* Recently received (within the last 4 weeks) or is anticipated to receive before the end of the study chemotherapy which can interfere with kidney function (e.g. Platinum agents).\n* Preoperative frailty (impaired mobility defined as patients requiring a wheelchair; and severe malnutrition defined as BMI \\\u003C16 kg\u002Fm²).\n* Patient previously enrolled and randomized into this study.\n* Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestate, confirmed by a positive human chorionic gonadotropin laboratory.\n* Known hypersensitivity to the study drug or any of its excipients.\n* Any medical or social condition deemed by the investigator to be likely to interfere with a patient's ability to give informed consent, cooperate, and participate in the study or to be likely to interfere with the interpretation of the results.\n* Patient who is in a relationship of dependency with the sponsor, investigator or trial site, or committed to an institution by virtue of an order issued by judicial or administrative authorities.",{"count":514,"type":22},430,[112],"This is a Phase 2, dose-ranging, double-blind, double-dummy, placebo-controlled, randomized study preceded by an open label safety run-in, in patients at high risk for Cardiac Surgery Associated - Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG), valve surgery, aortic surgery, or a combination of the above, involving cardiopulmonary bypass (CPB).\n\nSubjects are eligible for screening if they are scheduled for non-emergent CABG, valve surgery, surgery of the ascending part of the aorta, or a combination of the above, involving CPB, within 4 weeks after screening. In addition, subjects are eligible if AKI risk factors are present (at screening): a. If isolated surgery (CABG, single valve surgery, or of the ascending part of the aorta surgery) is scheduled, at least two AKI risk factors should be present b. If combined surgery is scheduled, at least one AKI risk factor should be present Risk factors for AKI are defined below: • Chronic kidney disease (CKD) stage III • Diabetes mellitus on pharmacological treatment • Confirmed diagnosis of hypertension • Documented history of Chronic Heart Failure with New York Heart Association (NYHA) class III or higher\n\n* Left ventricular ejection fraction (LVEF) ≤40%\n* Peripheral vascular disease defined as one or more of the following:\n\nclaudication, carotid occlusion or \\>50% stenosis, amputation for arterial disease, previous or planned intervention on the abdominal aorta, limb arteries or carotids.\n\n* Stroke\u002Ftransient ischemic attack (TIA) defined as sudden onset of focal or global brain, spinal cord, or retinal vascular damage, resulting in symptoms and signs of acute nervous system defects, which is associated with cerebral circulation disorders\n* Documented atrial fibrillation (AF) on the ECG performed at the screening visit\n* Anemia with hemoglobin ≤11 g\u002FdL at any time during the 3-month period before or at the time of screening\n* Body Mass Index (BMI) ≥ 30 kg\u002Fm2\n* Age ≥70 years at the time of screening The first dose of Investigational Medicinal Product (IMP: R2R01 or Placebo) will be administered subcutaneously (SC) the day before surgery at 06:00 PM (+\u002F- 30 min); the second dose will be administered SC on the day of surgery between 07:00 and 08:00 AM when the surgery is scheduled for the morning, or between 11:00 AM and 12:00 PM when the surgery is scheduled for the afternoon; subsequent doses will be administered SC every 24 hours (+\u002F- 90 min.) starting 24 hours after the second dose, and will continue to be administered until postoperative Day 5 or discharge, whichever occurs first. The follow-up period extends until postoperative Day 30.\n\nThe study consists of:\n\nA. An Open-Label Safety Run-In Part, followed by B. A Double-Blind, Placebo-Controlled, Randomized Part A. An Open-Label Safety Run-In Part The first 10 subjects will be treated with R2R01 5.0 mg SC to ascertain its safety in this population. The Safety Run-In part will be run at the San Raffaele Hospital in Milan (PI Dr. Landoni). Data collected will include but will not be limited to:\n\n(1) detailed hemodynamic parameters; (2) use of vasopressors and\u002For inotropic agents during surgery and in the postoperative period; (3) incidence, severity, and relationship of adverse events (AEs), including serious adverse events (SAEs); (4) postoperative clinical course; (5) available PK data.\n\nA Scientific Review Committee (SRC), consisting of three CSA-AKI experts and at least one medical representative of the Sponsor, will review the data from the 5.0 mg dose cohort (open-label Part), based on the safety and available pharmacokinetic data collected from the 10 enrolled patients through postoperative Day 7 or discharge, whichever occurs first. If the SRC agrees to proceed with the 5.0 mg dose, enrollment will open to the randomized part B of the study. If instead, the SRC determines that the 5.0 mg dose is not appropriate, a new dose (i.e., 2.5 mg) will be selected by the SRC for evaluation in 10 additional subjects enrolledin the open-label safety run-in part. Upon completion of the Open-Label Safety Run-In Part, and once the SRC has determined the appropriate R2R01 dose(s) to be tested, enrollment will open to the Double-Blind, Placebo-Controlled, Randomized Part. B. Double-Blind, Placebo-Controlled, Randomized Part Approximately 430 patients will be randomly assigned in a 1:1:1 manner to receive one of the two doses of R2R01or placebo. At randomization, patients will be stratified by presence of CKD stage III (strata: eGFR 59-30 ml\u002Fmin\u002F1.73m2 vs. eGFR ≥60 ml\u002Fmin\u002F1.73m2). The randomized part will be conducted at all investigational sites.\n\nAKI will be staged according to KDIGO as follows: Stage 1: increase in SCr ≥0.3 mg\u002FdL or an increase in serum creatinine ≥1.5-fold to 2-fold from baseline.\n\nStage 2: incrincrease in SCr \\>2-fold to 3-fold from baseline. Stage 3: increase in SCr \\>3-fold or SCr ≥4.0 mg\u002Fdl or initiation of renal replacement therapy (RRT)",[26],[519,26],"Cardiac Surgery Associated","2026-05-28",{"date":343,"type":36},{"date":523,"type":36},"2026-04-07",{"date":525,"type":22},"2027-04-30",{"name":527,"class":43},"River 2 Renal Corp.",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":536,"targetDuration":538,"studyType":23,"phases":4,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":44},"100621014","insights-into-the-continuous-renal-replacement-therapy-to-critical-ill-patients-100621014","NCT07365111","Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients","Insights Into the Characteristics, Prescription and Delivery of Continuous Renal Replacement Therapy to Critical Ill Patients - The iCRRT Data Registry","iCRRT","Inclusion Criteria:\n\n1. Admission to an intensive care unit\n2. CRRT therapy\n\nExclusion Criteria:\n\n1. End-stage kidney disease\n2. CRRT \\\u003C24 hours",{"count":537,"type":22},100000,"90 Days","This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) worldwide. The study aims to examine similarities and differences in CRRT practices and outcomes among critically ill adult patients across a global network of medical centers.\n\nThe goal is to develop a large, comprehensive repository of data on CRRT practices and outcomes. This repository will enable characterization of variation in standard CRRT practices across medical centers. Natural variability in practice patterns-both between and within centers-will provide an opportunity to compare outcomes associated with different approaches and to generate high-quality preliminary data to inform future interventional trials.\n\nPrimary Objective\n\n\\- To describe global patient characteristics, CRRT modalities, and clinical outcomes among patients receiving CRRT.\n\nSecondary Objectives\n\n* To compare clinical outcomes across geographic regions and CRRT modalities.\n* To identify patient-level and practice-level predictors of outcomes.\n* To assess the impact of comorbid conditions (e.g., diabetes mellitus) on CRRT outcomes.\n\nExploratory Objectives\n\n* To evaluate long-term renal outcomes and patient-reported quality of life.\n* To explore health economics and resource utilization related to CRRT.\n\nStudy Population All patients receiving CRRT as part of routine clinical care in the ICU at participating centers will be eligible for inclusion.\n\nData Collection The study will support an epidemiological assessment of patients undergoing CRRT, including, but not limited to, demographics, underlying disease states, severity of illness, physiological support, indications for CRRT, and clinical outcomes. Outcomes of interest include ICU and hospital mortality, ICU and hospital length of stay, and renal recovery.",[268,26,541,236],"Renal Dialysis",[543,544,26,368],"Continue Renal Replacement Therapy","Dialysis",{"date":415,"type":36},{"date":35,"type":22},{"date":548,"type":22},"2036-12-31",{"name":320,"class":76},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":18,"minAge":558,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":56,"phases":561,"briefSummary":562,"conditions":563,"keywords":568,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":579},"100518226","ctsn-embolic-protection-trial-100518226","NCT06027788","CTSN Embolic Protection Trial","Embolic Protection in Patients Undergoing High-Risk Valve Surgery","EMPRO","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Planned de novo or redo:\n\n  * Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG\n  * Mitral valve replacement (MVR) ± CABG\n  * Mitral Valve Repair + CABG,\n  * Double\u002FTriple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure\u002Fexcision or partial\u002Fcomplete Maze procedure.\n  * Valve sparing aortic root replacement (David procedure)\n  * Valve sparing aortic root replacement (David procedure)\n* No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization\n* Ability to provide informed consent and comply with the protocol\n\nExclusion Criteria:\n\n* History of clinical stroke within 3 months prior to randomization\n* Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure\n* Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening\u002Fbaseline NIHSS score conducted prior to the catheterization\n* Active endocarditis at time of randomization with vegetation criteria\n* Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization\n* Participation in an interventional (drug or device) trial\n* Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair\n* Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator\n* Planned concomitant carotid endarterectomy during index surgical procedure","60 Years",{"count":560,"type":22},842,[58],"This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.",[564,565,26,566,567],"Delirium","Ischemic Stroke","Heart Valve Disease","Coronary Artery Disease",[569,142,570],"Embolic Protection","CardioGard","2026-05-26",{"date":468,"type":36},{"date":574,"type":36},"2023-09-18",{"date":576,"type":22},"2027-04-01",{"name":578,"class":76},"Icahn School of Medicine at Mount Sinai",28,{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":56,"phases":589,"briefSummary":591,"conditions":592,"keywords":596,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":99},"100542051","phase-3-bleeding-reduction-in-acute-and-chronic-kidney-patients-having-surgery-brackets-pilot-trial-100542051","NCT06337838","Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial","BRACKETS","Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:\n\n1. One of either:\n\n   1.1. eGFR \\\u003C25 ml\u002Fmin\u002F1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;\n2. Planned noncardiac surgery (elective, urgent, or emergency surgery);\n3. Expected to require at least an overnight hospital admission after surgery;\n4. Age ≥18 years; and\n5. Informed consent is obtained to participate in the BRACKETS-Pilot Trial.\n\nExclusion Criteria:\n\n1. Undergoing cardiac surgery;\n2. Undergoing intracranial neurosurgery;\n3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;\n4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;\n5. Hypersensitivity or known allergy to TXA;\n6. History of seizure disorder;\n7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;\n8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;\n9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or\n10. Previously enrolled in the BRACKETS-Pilot Trial.\n\nEligibility criteria specific to the desmopressin factorial component of trial\n\nInclusion criteria:\n\n1\\. Included in the TXA factorial.\n\nExclusion criteria:\n\n1. The hospital does not have access to desmopressin;\n2. Planned use of prophylactic desmopressin;\n3. Most recent serum sodium concentration \\\u003C 130 mEq\u002FL;\n4. Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or\n5. Hypersensitivity or known allergy to desmopressin.",{"count":136,"type":22},[590],"PHASE3","The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.",[593,26,594,595],"Chronic Kidney Diseases","Bleeding","Surgery",[597,598,599],"Major Noncardiac Surgery","Tranexamic Acid","Desmopressin","2026-05-20",{"date":602,"type":36},"2026-05-22",{"date":604,"type":36},"2025-06-09",{"date":606,"type":22},"2027-06",{"name":608,"class":76},"Hamilton Health Sciences Corporation",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":133,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":56,"phases":619,"briefSummary":620,"conditions":621,"keywords":624,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":44},"100639499","real-time-acute-kidney-injury-perioperative-prediction-clinical-trial-100639499","NCT07604662","Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial","Prediction of Acute Kidney Injury (AKI) After Surgery: A Pragmatic Three-Arm Cluster-Randomized Trial","ML-AKI","Inclusion Criteria:\n\n* Adults ≥18 years undergoing non-obstetric surgery at UCSF.\n* Inpatient cases with expected overnight stay.\n* Baseline eGFR ≥15 mL\u002Fmin\u002F1.73 m².\n* Managed by an attending anesthesiologist randomized to one of three arms (CRNAs\u002Fresidents follow attending).\n* Data available in the UCSF EHR for risk scoring and outcomes.\n\nExclusion Criteria:\n\n* Obstetric procedures.\n* Chronic dialysis patients.\n* Kidney transplant recipients.\n* Cases without baseline creatinine\u002FeGFR or missing essential EHR elements needed for scoring\u002Foutcomes (operational exclusions).\n* Outpatient procedures without expected overnight stay.",{"count":618,"type":22},25518,[58],"This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best\u002FOur Practice Advisory (BPA\u002FOPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs\u002Fresidents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL\u002Fmin\u002F1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg\u002FdL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.",[26,622,623],"Surgery Complications","Anesthesia",[26,625,626,627,628],"Surgical Outcomes","Machine Learning","Clinical Decision Support","Electronic Health Records","2026-05-19",{"date":602,"type":36},{"date":632,"type":22},"2026-10-15",{"date":634,"type":22},"2027-12-15",{"name":636,"class":76},"University of California, San Francisco",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":645,"targetDuration":4,"studyType":56,"phases":647,"briefSummary":648,"conditions":649,"keywords":650,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":44},"100544452","continuous-veno-venous-hemodialysis-and-continuous-veno-venous-hemodiafiltration-on-urea-reduction-rate-in-intensive-care-patient-100544452","NCT06369064","Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient","Comparison of the Effectiveness of Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patients With Acute Renal Injury : a Monocentric Controled Randomized Non Inferiority Open Labeled Study","CompEER","Inclusion criteria:\n\n* Adult patients hospitalized in ICU\n* Undergo RRT session because of AKI stage 3\n* At least one among criteria: pH \\\u003C 7,20 \u002F Blood urea \\> 30mM \u002F Fluid overload uncontrolled by with PaCO₂ \\\u003C 35 mmHg or mixed acidosis with PaCO₂ \\\u003C 50 mmHg.\n\n  * Oliguria lasting 72 hours or longer\n* Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization\n* Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation\n* Patient affiliated with Social Security.\n\nExclusion criteria:\n\n* End-stage chronic kidney disease on dialysis\n* Intoxication with a dialyzable toxin (lithium\n* Criteria for emergency dialysis initiation: hyperkaliemia \\>6,5mM with electrocardiographic signs\n* Medical contraindication to regional citrate: severe liver failure\n* Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding\n* Pregnant women, parturient or breast-feeding patient",{"count":646,"type":22},80,[58],"In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD).\n\nTo our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter).\n\nIn the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury.\n\nThe research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.",[26,240,368],[651,652,653],"continuous venovenous hemodiafiltration","continuous venovenous hemodialysis","urea reduction rate",{"date":655,"type":36},"2026-05-18",{"date":657,"type":36},"2024-07-03",{"date":659,"type":22},"2028-08-15",{"name":374,"class":76}]